Italia markets closed

Gilead Sciences Inc (GIS.SG)

Stuttgart - Stuttgart Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
66,32+2,83 (+4,46%)
Alla chiusura: 09:53PM CEST
Schermo intero
Chiusura precedente63,49
Aperto64,10
Denaro65,99 x 100000
Domanda66,02 x 100000
Min-Max giorno64,10 - 67,84
Intervallo di 52 settimane57,32 - 80,26
Volume563
Media Volume228
CapitalizzazioneN/D
Beta (mensile su 5 anni)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utili08 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

    LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr